World Markets

Dr. Reddy's Launches Aspirin And Extended-Release Dipyridamole Capsules In U.S.

A generic image of a line graph
Credit: Shutterstock photo

(RTTNews.com) - Dr. Reddy's Laboratories Ltd (RDY) announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration.

The Aggrenox brand and generic had U.S. sales of approximately $182 million MAT for the most recent twelve months ending in October 2018 according to IMS Health.

Dr. Reddy's Aspirin and Extended-Release Dipyridamole Capsules are available in 25 mg/200 mg strength with 60 count bottle size.

Read the original article on RTTNews (http://www.rttnews.com/2965151/dr-reddy-s-launches-aspirin-and-extended-release-dipyridamole-capsules-in-u-s.aspx)

For comments and feedback: contact editorial@rttnews.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks Economy

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More